Pyxis Tankers will not be rushed into spending its cash pile in hot secondhand markets. The Nasdaq-listed Greek owner of six ...

An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models. The consensus rating for Pyxis Oncology is "Strong Buy" ...

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

On June 23, 2026, the M/T “Pyxis Karteria” safely transited the Strait of Hormuz. Throughout the regional disruption, the vessel remained employed under her existing fixed-rate time charter and ...

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target. Wall Street analysts changed outlook on top names. For full changes ...

Fidelity Concord Street Trust-Fidelity Total Market Index Fund 90.2k Jul 31, 2026 0.11% 289,558 Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund 78.71k Jul 31, 2026 0.09% 252,655 ...

Amanda Bellucco-Chatham is an editor, writer, and fact-checker with years of experience researching personal finance topics. Specialties include general financial planning, career development, lending ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Trading Activity price-reliability indicator with 45 percent data coverage. Low activity replaces price-derived sentiment because the displayed market price may not be supported by meaningful trading.